2.70
-4.26%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Antengene Corp
Its shares trade on HKEX under the ticker 6996.HK. It has been listed since 20 November 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥122.6m and a net loss of CN¥278.4m. At that date it held total assets of CN¥1.46bn and shareholders' equity of CN¥748.3m.
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Nov 2020
- Employees
- 359
- Website
- antengene.com ↗
Leadership
Pay as last reported
- Dr. Jay MeiExecutive Chairman of the Board, Chief Executive Officer, since 2018CN¥15.4m
- Mr. Donald LungChief Financial Officer, Executive Director, since 2020CN¥8.9m
- Dr. Bo ShanChief Scientific Officer
- Mr. John ChinExecutive Director, Chief Business Officer, since 2020CN¥5.9m
- Dr. Xiaojing ZhangChief Medical Officer
- Mr. Yang CaoJoint Company Secretary
- Mr. Wai Chiu WongJoint Company Secretary
- Dr. Rafael FonsecaNon-Executive Independent Director
- Ms. Jing QianNon-Executive Independent DirectorCN¥458,000
- Mr. Sheng TangNon-Executive Independent DirectorCN¥458,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Antengene's ATG-010 treats relapsed/refractory multiple myeloma in Asia-Pacific markets.
- ATG-008 targets hepatocellular carcinoma and non-small cell lung cancer in Asia-Pacific regions.
- 359 full-time employees support clinical-stage biopharmaceutical development in Shanghai.
Weaknesses
- Limited product portfolio with only two clinical-stage drugs ATG-010 and ATG-008.
- Asia-Pacific focus restricts global market reach beyond regional markets.
- IPO in 2020 limits financial resources for broader expansion.
Opportunities
- Expanding ATG-010 to treat additional cancers in Asia-Pacific markets.
- Growing demand for biotech products in the Asian pharmaceutical sector.
- Potential partnerships with Asian healthcare providers for product distribution.
Threats
- Competition from established pharmaceutical companies in Asia-Pacific.
- Regulatory challenges in multiple Asian countries for drug approvals.
- Dependence on Asia-Pacific market for revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.